TRACON Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCON research report →
Companywww.traconpharma.com
TRACON Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications.
- CEO
- Craig R. Jalbert CIRA
- IPO
- 2015
- Employees
- 17
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $109.72K
- P/E
- -0.01
- P/S
- 0.01
- P/B
- -0.06
- EV/EBITDA
- 1.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.88%
- Op Margin
- -57.27%
- Net Margin
- -29.79%
- ROE
- 90.15%
- ROIC
- -4338.36%
Growth & Income
- Revenue
- $12.04M · 0.00%
- Net Income
- $-3,588,000 · 87.76%
- EPS
- $-2.20 · 92.15%
- Op Income
- $-6,898,000
- FCF YoY
- 114.00%
Performance & Tape
- 52W High
- $0.75
- 52W Low
- $0.00
- 50D MA
- $0.03
- 200D MA
- $0.04
- Beta
- 1.42
- Avg Volume
- 14.43K
Get TickerSpark's AI analysis on TCON
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 7, 24 | Lazar David E. | other | 0 |
| Mar 12, 24 | Brown Scott B. | other | 224,800 |
| Apr 20, 23 | Brown Scott B. | other | 3,500 |
| Mar 12, 24 | THEUER CHARLES | other | 518,300 |
| Oct 20, 23 | THEUER CHARLES | other | 3,500 |
| Apr 20, 23 | THEUER CHARLES | other | 3,500 |
| Apr 27, 23 | THEUER CHARLES | buy | 47,000 |
| Apr 26, 23 | THEUER CHARLES | buy | 3,999 |
| Apr 19, 23 | Johnson-Pratt Lisa | other | 18,000 |
| Apr 19, 23 | Lam Carol C. | other | 18,000 |
Our TCON Coverage
We haven't published any research on TCON yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TCON Report →